Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15306517 | 1.00 | MEN1 (0.44) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL15306518 | 0.85 | MEN1 (0.44) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL23562282 | 0.84 | MEN1 (0.43) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL25126862 | 0.84 | MEN1 (0.43) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL29049022 | 0.84 | MEN1 (0.43) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL26342483 | 0.82 | MEN1 (0.42) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL2087734 | 0.80 | RORC (0.43) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL23208961 | 0.80 | KMT2A (0.40) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL20799595 | 0.80 | MEN1 (0.40) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL23208962 | 0.80 | KMT2A (0.40) | MEN1MAPK1KMT2ANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381259-B2 | Precursor compound of radioactive halogen-labeled organic compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20160082135-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20160000944-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20140213817-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | NIHON-MEDI-PHYSICS CO., LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213817-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | BCAT2, SLCO2B1, ORC3 | MEN1 3670/4885MAPK1 1499/4885KMT2A 3576/4885 |
| US-20160082135-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | BCAT2, SLCO2B1, ORC3 | MEN1 3670/4885MAPK1 1499/4885KMT2A 3576/4885 |
| US-20160000944-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | BCAT2, SLCO2B1, ORC3 | MEN1 3670/4885MAPK1 1499/4885KMT2A 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.